Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7928886 | 0.89 | GPR119 (0.47) | USP30GPR119BCHEHTR6SFRP1 | |
| SCHEMBL2189813 | 0.86 | CACNA1B (0.52) | USP30GPR119SFRP1STSTGFBR1 | |
| SCHEMBL29171198 | 0.85 | RORC (0.42) | USP30GPR119STSTGFBR1 | |
| SCHEMBL845706 | 0.81 | GPR119 (0.47) | USP30GPR119SFRP1STSTGFBR1 | |
| SCHEMBL859745 | 0.81 | GPR119 (0.47) | USP30GPR119SFRP1STSTGFBR1 | |
| SCHEMBL7930215 | 0.80 | USP30 (0.51) | USP30GPR119HPGDSACKR3PRMT5 | |
| SCHEMBL970903 | 0.79 | USP30 (0.53) | USP30GPR119HPGDSACKR3PRMT5 | |
| SCHEMBL970901 | 0.79 | USP30 (0.53) | USP30GPR119HPGDSACKR3PRMT5 | |
| SCHEMBL3325435 | 0.79 | USP30 (0.53) | USP30GPR119HPGDSACKR3PRMT5 | |
| SCHEMBL12631529 | 0.79 | USP30 (0.53) | USP30GPR119HPGDSACKR3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| WO-2010036589-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | USP30 3244/4885GPR119 136/4885BCHE 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.